Limitation of infarct size with preconditioning and calcium antagonist (diltiazem): difference in 99mTc-PYP uptake in the myocardium

Ann Nucl Med. 1996 May;10(2):201-9. doi: 10.1007/BF03165393.

Abstract

Ischemic cell injury and the uptake mechanism of 99mTc-PYP (Pyrophosphate) were studied with preconditioning and calcium antagonist.

Method: The coronary artery of an adult mongrel dog was clamped for 1 hour, followed by reperfusion and 99mTc-PYP injection. A control group (group C, n = 8), a group in which continuous drip infusion of diltiazem (10 mg/kg) (group D, n = 7), and a group preconditioned by six 5-minute clampings and perfusions before occlusion (group P, n = 6) were compared.

Results: Wall motion was fully recovered in group D but not in group P after 2 hours of reperfusion. The 99mTc-PYP uptake ratio showed a significant (p < 0.05) reduction in group D (11.5 : 3.6 compared with group C), but not in group P (11.5 : 9.1, p = 0.25). The infarct area was 1.2 +/- 0.6% of the left ventricle in group D, 1.3 +/- 0.4 in group P, and 6.4 +/- 1.0 in group C (p < 0.01 in groups D and P vs. group C).

Conclusions: These findings suggest that preconditioning does not alleviate stunning, but it improves cell injury in spite of high uptake of 99mTc-PYP. Diltiazem protects from both stunning and cell injury, suggesting a different mechanism of myocardial protection from that of preconditioning.

MeSH terms

  • Animals
  • Calcium Channel Blockers / pharmacology*
  • Coronary Circulation* / drug effects
  • Diltiazem / pharmacology*
  • Dogs
  • Myocardial Infarction / diagnostic imaging*
  • Myocardial Infarction / pathology*
  • Myocardial Infarction / physiopathology
  • Myocardial Ischemia / diagnostic imaging
  • Myocardial Ischemia / physiopathology
  • Radionuclide Imaging
  • Technetium Tc 99m Pyrophosphate / pharmacokinetics*

Substances

  • Calcium Channel Blockers
  • Technetium Tc 99m Pyrophosphate
  • Diltiazem